Pediatric Dose of Steroids for Infantile Epileptic Spasms Syndrome
For infantile epileptic spasms syndrome (IESS), the recommended dose of oral prednisolone is 40-60 mg/day (or 2-8 mg/kg/day, maximum 60 mg/day) given as a single daily dose for 2 weeks, followed by a taper over 2-5 weeks.
Initial Treatment Dosing
The evidence supports starting with prednisolone 40 mg/day as first-line therapy, with escalation to higher doses if needed 1, 2. Recent high-quality research demonstrates:
- Standard dose: 40 mg/day achieves spasm cessation in approximately 63% of patients 2
- High dose: 8 mg/kg/day (maximum 60 mg/day) achieves complete electroclinical response in 77.8% of vigabatrin-refractory cases 3
- Duration: 2 weeks at full dose, followed by tapering over 2-5 weeks 1, 3
The FDA label for prednisolone confirms dosing ranges of 0.14 to 2 mg/kg/day for pediatric conditions, with flexibility based on disease severity 4.
Sequential Treatment Algorithm
Step 1: Start prednisolone 40 mg/day (or 2 mg/kg/day) for 2 weeks
- If spasms cease: taper over 2-5 weeks
- If spasms persist: proceed to Step 2
Step 2: Escalate to prednisolone 60 mg/day (or up to 8 mg/kg/day, maximum 60 mg/day) for 2 weeks 2
- 41% of initial non-responders achieve spasm cessation with dose escalation
- If spasms persist: proceed to Step 3
Step 3: Add or switch to vigabatrin or consider ACTH 2, 5
- 45% of prednisolone non-responders respond to vigabatrin
- The UKISS sequential approach achieves 83% overall response rate 2
Prednisolone vs. ACTH: The Evidence
Prednisolone and ACTH show equivalent short-term efficacy for spasm cessation (70% vs 63%, p=0.28) 1. A 2021 meta-analysis of randomized trials found no statistically significant difference in 14-day spasm resolution between ACTH and high-dose prednisolone (4-8 mg/kg/day), with an odds ratio of 0.92 (95% CI 0.34-2.52, p=0.87) 6.
However, prednisolone is dramatically more cost-effective, with an incremental cost-effectiveness ratio of $333 per case resolved versus $1,432,200 for ACTH 6. The 2025 Chinese economic evaluation confirmed prednisolone costs 5.56 yuan versus 5,629.19 yuan for ACTH within 14 days 7.
ACTH may offer advantages in:
- Improving electroclinical response on EEG (RR=1.46, p=0.01) 7
- Reducing time to relapse (mean difference 1.65 months) 7
Administration Details
- Timing: Give as single morning dose to minimize HPA axis suppression 4
- Duration at full dose: 2 weeks (not longer—no added benefit and increased side effects) 8, 3
- Tapering: Reduce over 2-5 weeks after achieving spasm cessation 1, 2
- Monitoring: Assess for spasm cessation and electroclinical response at 2 weeks 1, 3
Common Pitfalls to Avoid
- Underdosing: Using doses <40 mg/day or <2 mg/kg/day reduces efficacy
- Prolonged high-dose therapy: Extending beyond 2 weeks at maximum dose increases adverse effects without improving outcomes 8
- Inadequate tapering: Abrupt discontinuation increases relapse risk—always taper gradually 4
- Delaying treatment: Earlier treatment initiation improves outcomes; don't delay for extensive workup 9
- Insurance barriers: 72% of centers report prior authorization delays affecting treatment pathways 9
Safety Considerations
High-dose prednisolone (8 mg/kg/day) is generally well-tolerated in IESS 3. Common adverse effects include:
- Irritability and sleep disturbance
- Increased appetite and weight gain
- Hypertension (monitor blood pressure)
- Gastrointestinal symptoms (79% of centers use GI prophylaxis) 9
Prednisolone has significantly fewer severe adverse effects compared to ACTH in head-to-head trials 10.
Special Populations
For tuberous sclerosis complex with IESS: Vigabatrin is preferred first-line due to specific efficacy in this etiology. Prednisolone remains appropriate for TSC patients who fail or cannot tolerate vigabatrin 9.
For cryptogenic/unknown etiology: Prednisolone 40-60 mg/day remains the evidence-based first choice, with the sequential escalation approach if needed 2.